James C. Fang
( out of 173 reviews )

James C. Fang, MD

Languages spoken: English

Clinical Locations

Primary Location

Redstone Health Center

1743 W Redstone Center Drive
Park City , UT 84098
435-658-9200
Get Directions

University of Utah Hospital

50 N Medical Dr
Salt Lake City , UT 84132
801-585-7676
Get Directions

Cardiovascular Center

Cardiovascular Center
50 N Medical Dr
Salt Lake City , UT 84132
801-585-7676
Get Directions

James Chen-tson Fang, M.D., is the Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiovascular Service Line at University of Utah Health Care. He holds the John and June B. Hartman Presidential Endowed Chair and is Professor of Medicine at the University of Utah School of Medicine.

Dr. Fang graduated from Duke University with a major in Mathematics and minor in Chemistry (1984) and received his medical degree from the Duke University School of Medicine (1988). He completed his internship and residency at the Johns Hopkins Hospital (1991) and was selected as an Assistant Chief of Service (Chief Resident) for the Johns Hopkins Hospital (1993). He completed his cardiovascular (1996) and heart failure/transplant fellowships (1997) at Brigham and Women’s Hospital/Harvard Medical School.

His first faculty appointment was at the Brigham and Women’s Hospital/Harvard Medical School in 1997, where he remained until 2006. He served as Associate Professor of Medicine, Medical Director of the Heart Transplant Program as well as Program Director of the Cardiovascular Fellowship Training Program during his tenure in Boston.

In 2006, he was recruited to University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine/Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program and Chief Medical Officer for the Harrington Heart and Vascular Institute. While in Cleveland, he also held the Spitz Master Clinician Chair at Case Western Reserve University School of Medicine, where he was a Professor of Medicine.

In 2013, he assumed the role of Chief of Cardiovascular Medicine at the University of Utah and Executive Director of the UU Health’s Cardiovascular Service Line. Dr. Fang’s role at the University of Utah includes leading efforts to ensure the institution is recognized as a premier clinical, educational, and research institution for cardiovascular disease. He continues to develop highly skilled multidisciplinary teams that provide comprehensive, personalized and cost-effective care, and oversees the research, education and clinical care programs of the Cardiovascular Division.

Dr. Fang is a highly regarded clinician, teacher, mentor and researcher. He is the author of more than 175 original articles, editorials, and book chapters and has lectured nationally and internationally. He has been part of a number of important cardiovascular research groups and collaborations and has special interest in heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and the cardiorenal syndrome. He has led several position statements for the Heart Failure Society of America as well as the International Society for Heart and Lung Transplantation. He currently serves on the ACC/AHA Heart Failure Guideline Committee and on the Board of Directors of the Heart Failure Society of America. He was elected to the Association of University Cardiologists in 2013 and is a member of the Executive Committee of the Association of Professors of Cardiology.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Advanced Heart Failure & Transplant Cardiology)

Patient Rating

5.0 /5
( out of 173 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

REDSTONE HEALTH CENTER

efficient and knowledgeable about a disease other than my cardiac disease

REDSTONE HEALTH CENTER

I highly respect Dr.Fang but I felt this was very impersonal, and somewhat defensive of my, I'm sure, dumb questions. He was curt and somewhat dismissive and gave me the same old blah blah. Lose 20 pounds,ride a workout bike 30 minutes a day, cut my alcohol in half,no salt at 72 and I have a 1 in 4 chance in the next 10 years of having a stroke or a heart attack if I don't do this. I'm sure he isa brilliant doctor with a tremendous pedigree but I was hoping maybe for a middel ground for doing better. There is a ying and a yang to life,not all or nothing for a quality balance of life.

REDSTONE HEALTH CENTER

Excellent experience with Dr. Fang talking with me and not facing a computer.

REDSTONE HEALTH CENTER

Dr. Fang spent much time with me, answering my questions clearly, explaining my issues, and slowing much concern for my next steps. He promptly followed up with my ophthalmologist, and called me back right away.

UH HOSPITALS AND CLINICS

Have have a patient of Dr Fangs for 7 years and very confident in his expertise

UH HOSPITALS AND CLINICS

I love this man! Hes a wonderful doctor and person!

REDSTONE HEALTH CENTER

Dr. Fang was professional, polite, and explained everything very well such that I felt very comfortable with the plan moving forward.

REDSTONE HEALTH CENTER

In a short 3 weeks, Dr Fang has made more progress than I have experienced in the past 3 months. By any measure he is an "Outstanding" Cardiologist

REDSTONE HEALTH CENTER

Excellent physician

James Chen-tson Fang, M.D., is the Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiovascular Service Line at University of Utah Health Care. He holds the John and June B. Hartman Presidential Endowed Chair and is Professor of Medicine at the University of Utah School of Medicine.

Dr. Fang graduated from Duke University with a major in Mathematics and minor in Chemistry (1984) and received his medical degree from the Duke University School of Medicine (1988). He completed his internship and residency at the Johns Hopkins Hospital (1991) and was selected as an Assistant Chief of Service (Chief Resident) for the Johns Hopkins Hospital (1993). He completed his cardiovascular (1996) and heart failure/transplant fellowships (1997) at Brigham and Women’s Hospital/Harvard Medical School.

His first faculty appointment was at the Brigham and Women’s Hospital/Harvard Medical School in 1997, where he remained until 2006. He served as Associate Professor of Medicine, Medical Director of the Heart Transplant Program as well as Program Director of the Cardiovascular Fellowship Training Program during his tenure in Boston.

In 2006, he was recruited to University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine/Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program and Chief Medical Officer for the Harrington Heart and Vascular Institute. While in Cleveland, he also held the Spitz Master Clinician Chair at Case Western Reserve University School of Medicine, where he was a Professor of Medicine.

In 2013, he assumed the role of Chief of Cardiovascular Medicine at the University of Utah and Executive Director of the UU Health’s Cardiovascular Service Line. Dr. Fang’s role at the University of Utah includes leading efforts to ensure the institution is recognized as a premier clinical, educational, and research institution for cardiovascular disease. He continues to develop highly skilled multidisciplinary teams that provide comprehensive, personalized and cost-effective care, and oversees the research, education and clinical care programs of the Cardiovascular Division.

Dr. Fang is a highly regarded clinician, teacher, mentor and researcher. He is the author of more than 175 original articles, editorials, and book chapters and has lectured nationally and internationally. He has been part of a number of important cardiovascular research groups and collaborations and has special interest in heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and the cardiorenal syndrome. He has led several position statements for the Heart Failure Society of America as well as the International Society for Heart and Lung Transplantation. He currently serves on the ACC/AHA Heart Failure Guideline Committee and on the Board of Directors of the Heart Failure Society of America. He was elected to the Association of University Cardiologists in 2013 and is a member of the Executive Committee of the Association of Professors of Cardiology.

Board Certification and Academic Information

Academic Departments Internal Medicine -Professor
Academic Divisions Cardiovascular Medicine
Board Certification
American Board of Internal Medicine (Sub: Advanced Heart Failure & Transplant Cardiology)

Education history

Undergraduate Duke University B.A.
Professional Medical Medicine - Duke University School of Medicine M.D.
Internship/Residency Osler Medical Service - Johns Hopkins Hospital Intern/Resident
Clerkship Medicine Preceptor - Johns Hopkins School of Medicine Clerkship
Chief Resident Assistant Chief of Service, Osler Medical Service - Johns Hopkins Hospital Chief Resident
Fellowship Cardiovascular Disease - Brigham and Women¿s Hospital Clinical Fellow
Post Graduate Training Program in Clinical Effectiveness - Harvard School of Public Health Postgraduate Studies
Fellowship Heart Failure and Cardiac Transplantation - Brigham and Women¿s Hospital Fellow
Research Fellow Cardiovascular Disease - Brigham and Women¿s Hospital Research Fellow

Selected Publications

Journal Article

  1. Sundaram V, Chaudhry SP, Reddy YN, Longenecker CT, Fang J (2015). Emergent cesarean section in the catheterization laboratory for spontaneous coronary artery dissection. The American journal of cardiology, 115(12), 1777-8.
  2. Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang J (2011). Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Archives of internal medicine, 171(16), 1454-62.
  3. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg-Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza R (2012). World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. The Journal of heart and lung transplantation, 31(9), 913-33.
  4. Yin MY, Wever-Pinzon O, Mehra MR, Selzman CH, Toll AE, Cherikh WS, Nativi-Nicolau J, Fang JC, Kfoury AG, Gilbert EM, Kemeyou L, McKellar SH, Koliopoulou A, Vaduganathan M, Drakos SG, Stehlik (2019). Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. The Journal of heart and lung transplantation, 38(8), 858-869.
  5. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, Navaravong L, Piccini JP, Ranjan R, Spertus JA, Stehlik J, Turner JL, Greene T, Hess R, Steinberg B (2020). Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. Journal of cardiovascular electrophysiology, 31(12), 3187-3195.
  6. Morrow DA, Fang JC, Fintel DJ, Granger CB, Katz JN, Kushner FG, Kuvin JT, Lopez-Sendon J, McAreavey D, Nallamothu B, Page RL 2nd, Parrillo JE, Peterson PN, Winkelman (2012). Evolution of critical care cardiology: transformation of the cardiovascular intensive care unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association. Circulation, 126(11), 1408-28.
  7. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 127(4), e362-425.
  8. Hegde SM, Claggett B, Shah AM, Lewis EF, Anand I, Shah SJ, Sweitzer NK, Fang JC, Pitt B, Pfeffer MA, Solomon S (2017). Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation, 136(11), 982-992.
  9. Badolia R, Ramadurai DKA, Abel ED, Ferrin P, Taleb I, Shankar TS, Krokidi AT, Navankasattusas S, McKellar SH, Yin M, Kfoury AG, Wever-Pinzon O, Fang JC, Selzman CH, Chaudhuri D, Rutter J, Drakos S (2020). The Role of Nonglycolytic Glucose Metabolism in Myocardial Recovery Upon Mechanical Unloading and Circulatory Support in Chronic Heart Failure. Circulation, 142(3), 259-274.
  10. Shah KS, Moslehi JJ, Fang J (2020). Tissue is the Issue, Even During a Pandemic. Circulation, 142(5), 423-425.
  11. Byrne KR, Panagiotakis PH, Hilden K, Thomas KL, Peterson KA, Fang J (2007). Retrospective analysis of esophageal food impaction: differences in etiology by age and gender. Digestive diseases and sciences, 52(3), 717-21.
  12. Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola T (2011). The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. Journal of the American College of Cardiology, 58(4), 386-94.
  13. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao D (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61(4), 485-510.
  14. Ky B, French B, May Khan A, Plappert T, Wang A, Chirinos JA, Fang JC, Sweitzer NK, Borlaug BA, Kass DA, St John Sutton M, Cappola T (2013). Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. Journal of the American College of Cardiology, 62(13), 1165-72.
  15. Wilcox JE, Fang JC, Margulies KB, Mann D (2020). Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. Journal of the American College of Cardiology, 76(6), 719-734.
  16. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators (2019). Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 1-10.
  17. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, Starling R (2012). Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. Journal of cardiac failure, 18(2), 94-106.
  18. Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling R (2012). Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. Journal of cardiac failure, 18(4), 265-81.
  19. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling R (2013). Acute decompensated heart failure: update on new and emerging evidence and directions for future research. Journal of cardiac failure, 19(6), 371-89.
  20. Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK, Cappola T (2014). Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. Journal of cardiac failure, 20(8), 569-76.
  21. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, Starling R (2012). Heart Failure Society of America Guideline Committee.Indications for CRT: 2011 Update from the HFSA Guideline Committee. Journal of cardiac failure, 18(2), 94-106.
  22. Kalogeropoulos AP, Thankachen J, Butler J, Fang J (2020). Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. European journal of heart failure, 22(9), 1600-1610.
  23. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE, GALACTIC-HF Investigators (2020). Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. European journal of heart failure, 22(11), 2160-2171.
  24. Pepin ME, Drakos S, Ha CM, Tristani-Firouzi M, Selzman CH, Fang JC, Wende AR, Wever-Pinzon (2019). DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure. American journal of physiology. Heart and circulatory physiology, 317(4), H674-H684.
  25. Shah KS, Fang J (2019). Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?. Current hypertension reports, 21(11), 86.
  26. Welt FGP, Fang J (2019). Pressure Volume System for Management of Heart Failure and Valvular Heart Disease. Current cardiology reports, 21(12), 153.
  27. Steinberg BA, Turner J, Lyons A, Biber J, Chelu MG, Fang JC, Freedman RA, Han FT, Hardisty B, Marrouche NF, Ranjan R, Shah RU, Spertus JA, Stehlik J, Zenger B, Piccini JP, Hess (2020). Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. Europace, 22(3), 368-374.
  28. Taleb I, Wever-Pinzon J, Wang W, Koliopoulou A, Dranow E, Yu T, Yin L, McKellar SH, Stehlik J, Fang JC, Wever-Pinzon O, Selzman CH, Drakos S (2020). Outcomes of Asian-Americans Implanted With Left Ventricular Assist Devices: An Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Analysis. Heart, lung & circulation, 29(8), 1226-1233.
  29. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, Goldberg LR, Jessup M, Cappola T (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circulation. Heart failure, 5(2), 183-90.
  30. Symons JD, Deeter L, Deeter N, Bonn T, Cho JM, Ferrin P, McCreath L, Diakos NA, Taleb I, Alharethi R, McKellar S, Wever-Pinzon O, Navankasattusas S, Selzman CH, Fang JC, Drakos S (2019). Effect of Continuous-Flow Left Ventricular Assist Device Support on Coronary Artery Endothelial Function in Ischemic and Nonischemic Cardiomyopathy. Circulation. Heart failure, 12(8), e006085.
  31. Minamisawa M, Seidelmann SB, Claggett B, Hegde SM, Shah AM, Desai AS, Lewis EF, Shah SJ, Sweitzer NK, Fang JC, Anand IS, O'Meara E, Rouleau JL, Pitt B, Solomon S (2019). Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. JACC. Heart failure, 7(8), 664-675.
  32. Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, O'Meara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD, TOPCAT Investigators (2019). Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. JACC. Heart failure, 7(12), 1022-1028.
  33. Yin MY, Strege J, Gilbert EM, Stehlik J, McKellar SH, Elmer A, Anderson T, Aljuaid M, Nativi-Nicolau J, Koliopoulou AG, Davis E, Fang JC, Drakos SG, Selzman CH, Wever-Pinzon (2020). Impact of Shared Care in Remote Areas for Patients With Left Ventricular Assist Devices. JACC. Heart failure, 8(4), 302-312.
  34. Chandra A, Alcala MAD, Claggett B, Desai AS, Fang JC, Heitner JF, Liu J, Pitt B, Solomon SD, Pfeffer MA, Lewis E (2020). Associations Between Depressive Symptoms and HFpEF-Related Outcomes. JACC. Heart failure, 8(12), 1009-1020.

Book Chapter

  1. Ryan J, Natvi J, Fang J (2015). Hemodynamics in Heart Failure.

Case Report

  1. Chow CH, El-Amm C, Liu W, Pastva S, Sipahi I, Fang J (2013). Reversal of severe biventricular dysfunction from cardiac hemochromatosis with iron removal. Circulation. Heart failure, 6(1), e14-5.

Editorial

  1. Ryan JJ, Fang J (2015). Pulmonary hypertension in heart failure: measurable, but how meaningful?. The Journal of heart and lung transplantation, 34(3), 310-1.
  2. Fang J (2012). Heart failure therapy: what should clinicians believe?. JAMA, 308(20), 2144-6.
  3. Fang J (2019). Heart-Failure Therapy - New Drugs but Old Habits?. The New England journal of medicine, 381(21), 2063-2064.
  4. Shah KS, Fang J (2019). Treating the Cardiorenal Syndrome: A Sledgehammer for a Needle's Work?. Journal of cardiac failure, 25(11), 935-936.
  5. Ibrahim MM, Fang J (2019). Magnetic Resonance Imaging of Cardiac Allografts: What's Next?. Circulation. Cardiovascular imaging, 12(10), e009784.
  6. Fang JC, Jones T (2020). Can a Pulmonary Artery Catheter Improve Outcomes in Cardiogenic Shock?. JACC. Heart failure, 8(11), 914-916.

Letter

  1. Taleb I, Koliopoulou AG, Tandar A, McKellar SH, Tonna JE, Nativi-Nicolau J, Alvarez Villela M, Welt F, Stehlik J, Gilbert EM, Wever-Pinzon O, Morshedzadeh JH, Dranow E, Selzman CH, Fang JC, Drakos S (2019). Shock Team Approach in Refractory Cardiogenic Shock Requiring Short-Term Mechanical Circulatory Support: A Proof of Concept. Circulation, 140(1), 98-100.
  2. Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, Sweitzer NK, Fang JC, O'Meara E, Shah SJ, Shah AM, Lewis EF, Rouleau J, Pitt B, Solomon S (2019). Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. European journal of heart failure, 21(10), 1288-1291.
  3. Ramalho SHR, Claggett BL, Sweitzer NK, Fang JC, Shah SJ, Anand IS, Pitt B, Lewis EF, Pfeffer MA, Solomon SD, Shah A (2020). Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. European journal of heart failure, 22(3), 557-559.

Video/Film/CD/Web/Podcast

  1. Fang JC, Pinney (2014). Cardiac Transplantation (webinar).

News & Podcasts

News

Podcasts